Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536423 | 1.00 | CTSS (0.49) | CTSSCTSKRENPPARAPPARG | |
| SCHEMBL8215508 | 0.96 | CTSS (0.46) | CTSSCTSKRENPPARAPPARG | |
| SCHEMBL1486176 | 0.94 | PPARA (0.47) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL1001711 | 0.94 | PPARA (0.47) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL1001713 | 0.94 | PPARA (0.47) | CTSSCTSKPPARAPPARGCTSL | |
| SCHEMBL11418050 | 0.91 | CTSS (0.60) | CTSSCTSKRENPPARAPPARG | |
| SCHEMBL30685552 | 0.91 | CTSS (0.60) | CTSSCTSKRENPPARAPPARG | |
| SCHEMBL24049238 | 0.91 | CTSL (0.56) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL10788830 | 0.89 | REN (0.47) | CTSSCTSKRENPPARAPPARG | |
| SCHEMBL28501209 | 0.89 | REN (0.47) | CTSSCTSKRENPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | N-ZYME BIOTECH GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002036798-A2 | INHIBITORS OF TRANSGLUTAMINASES | N-ZYME BIOTEC GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | TGM2, GNMT, TGM1 | CTSS 1533/4885CTSK 1962/4885REN 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.